Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Insta360 Debuts on the STAR Market with a 285% Surge, Market Value Exceeds CNY 70 Bn

On June 11, Insta360 (stock code: 688775.SH), a leading Chinese intelligent imaging company, officially listed on the Shanghai Stock Exchange's STAR Market. According to the prospectus, the offering price was CNY 47.27 per share, corresponding to a post-IPO market value of approximately CNY 18.96 billion. On its first day of trading, the opening price was CNY 182 per share, representing a 285% increase from the offering price, with the total market value surpassing CNY 70 bn.

CHANGAN Automobile Plans 20 Overseas Plants Globally, Expanding into Over 100 Countries

On June 7, the 27th Chongqing International Auto Exhibition officially opened. As a leading local car manufacturer in Chongqing, CHANGAN Automobile participated under the theme "Together for A Smarter World", showcasing its full brand matrix and presenting its phased achievements and future plans in new energy, intelligence, and globalization.

BYD: Global Expansion and Premiumization Are Key Strategies

On June 6, the 2024 Annual Shareholders’ Meeting of Chinese electric vehicle manufacturer BYD was held. BYD’s Chairman and CEO, Wang Chuanfu, addressed shareholder concerns regarding the company’s overseas market expansion, electrification, and intelligent technologies, emphasizing that both international expansion and premiumization are critical strategies for BYD.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.